Who
Rory B. Riggs
Director
Company insider
Files Form 4 as: Chief Executive Officer, Cibus; Director, Intra-Cellular Therapies; Director, Royalty Pharma; Director, Kyntra Bio.
In numbers
- Trades disclosed
- 251
- Buys
- 6
- Sells
- 41
- Bought
- $6.9M
- Sold
- $253.6M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 12 Dec 2002
- Last trade
- 2 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jun 2026filed 4 Jun 2026 | CBUS Cibusoption or derivative · Agricultural Chemicals & Fertilizers | SEC FORM 4 Code A | —77,586 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | CBUS Cibusoption or derivative · Agricultural Chemicals & Fertilizers | SEC FORM 4 Code A | —77,586 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | CBUS CibusAgricultural Chemicals & Fertilizers | SEC FORM 4 Code A | $500K333,333 at $1.50 | filing |
| 29 Jan 2026filed 2 Feb 2026 | CBUS CibusAgricultural Chemicals & Fertilizers | SEC FORM 4 Code A | $500K333,333 at $1.50 | filing |
| 9 Jun 2025filed 11 Jun 2025 | CBUS Cibusoption or derivative · Agricultural Chemicals & Fertilizers | SEC FORM 4 Code X | —4,000,000 at $0.00 | filing |
| 9 Jun 2025filed 11 Jun 2025 | CBUS Cibusoption or derivative · Agricultural Chemicals & Fertilizers | SEC FORM 4 Code X | —50,000 at $0.00 | filing |
| 9 Jun 2025filed 11 Jun 2025 | CBUS CibusAgricultural Chemicals & Fertilizers | SEC FORM 4 Code X | —4,000,000 at $0.00 | filing |
| 9 Jun 2025filed 11 Jun 2025 | CBUS CibusAgricultural Chemicals & Fertilizers | SEC FORM 4 Code X | $50050,000 at $0.01 | filing |
| 5 Jun 2025filed 10 Jun 2025 | CBUS CibusAgricultural Chemicals & Fertilizers | SEC FORM 4 Code A | $10.0M5,714,286 at $1.75 | filing |
| 22 May 2025filed 27 May 2025 | CBUS Cibusoption or derivative · Agricultural Chemicals & Fertilizers | SEC FORM 4 Code A | —39,301 at $0.00 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —16,757 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —7,009 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —4,322 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —2,951 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapies | SEC FORM 4 Code D | $17.4M131,512 at $132.00 | filing |
| 21 Jan 2025filed 23 Jan 2025 | CBUS Cibusoption or derivative · Agricultural Chemicals & Fertilizers | SEC FORM 4 Code A | —4,000,000 | filing |
News
Kyntra Bio (KYNB): Can Its New Strategy And Pipeline Revive Investor Interest?KYNB · rttnews.com · 19 Oct 2026Royalty Pharma (NASDAQ:RPRX) and Aditxt (NASDAQ:ADTX) Financial ComparisonRPRX · themarketsdaily.com · 18 Oct 2026Kyntra Bio Inc (KYNB) – What Are Brokerages Saying About This Stock?KYNB · dailypolitical.com · 14 Oct 2026Prothena (NASDAQ:PRTA) vs. Kyntra Bio (NASDAQ:KYNB) Financial ReviewKYNB · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Rory B. Riggs; 4 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.